Navigation Links
PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
Date:11/20/2008

BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it has opened an office in Lima, Peru to provide regulatory consulting and clinical research capabilities. With the addition of the Peru office, PAREXEL now has locations throughout five important biopharmaceutical centers in Latin America, which also include Argentina, Brazil, Chile, and Mexico. This expansion further strengthens the Company's position as one of the largest biopharmaceutical services providers in this emerging region for clinical development.

"PAREXEL has had a presence in Latin America since 1997, and a long-term commitment to providing clients with high quality services in the region. Due to the increasing globalization of clinical research, client demand for our capabilities in Latin America has been steadily increasing, and over the last seven years PAREXEL has experienced double-digit growth in the region. Peru is a key growing market in Latin America, with approximately 28 million people. The opening of our Peru office marks a significant opportunity for clients to further expand their clinical development programs throughout Latin America," said Josef H. von Rickenbach, Chairman and Chief Executive Officer of PAREXEL. "Our experts in Latin America manage complex clinical trials on a regional and worldwide scale. Included among the broad array of services we provide, we are helping clients to navigate regulatory environments, identify qualified investigators, and access diverse patient populations throughout the region."

Capabilities provided by PAREXEL's Latin American locations include regulatory advice for clinical development, as well as a broad range of services including project management, site management, data management, medical a
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
7. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
8. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
9. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
10. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2009)...ERFIELD, Ill., June 26, and OSAKA, Japan, June 27,...y Limited ("Takeda") today announced that Takeda G...holly owned United States (U.S.) subsidiary receiv...er from the U.S. Food and Drug Administration (FDA...A) for alogliptin, a selective dipeptidyl peptidas...
(Date:6/26/2009)...sitive Opinion Recommends Approval of New Anti-TNF...artJect(TM) Autoinjector , , HORSHAM, Pa. and K... Centocor Ortho Biotech Inc. and Schering-Plough C... Committee for Medicinal Products for Human Use (C...ed a positive opinion recommending the approval of...
(Date:6/25/2009)...mpany Also Receives Patent Covering ARIKACE for On..., , MONMOUTH JUNCTION, N.J., June 25 /PRNewswir..., the nonprofit affiliate of the Cystic Fibrosis F...ansave Inc., for the continued development of ARIK...tibiotic that aims to treat Pseudomonas lung inf...
(Date:6/24/2009)...udy shows 4% CHG antiseptic is effective against a...une 24 Hand washing with a 4% chlo...product is one effective way to stop the spread of...ptic/Antimicrobial Skin Cleanser and Hibistat Heal...een tested and found to be effective against a var...
Breaking Medicine Technology:Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4Hand Washing with 4% CHG Antiseptic Kills Flu Viruses 2Medco Launches Medicare Part D Initiative to Promote ePrescribing 11610 1Medco Launches Medicare Part D Initiative to Promote ePrescribing 11610 2Medco Launches Medicare Part D Initiative to Promote ePrescribing 11610 3Medco Launches Medicare Part D Initiative to Promote ePrescribing 11610 4Founding CEOS of SureScripts 28R 29 and RxHub 28R 29 Join Forces to Deliver Clinical Information Technology Services to Physician Practices 11607 1Founding CEOS of SureScripts 28R 29 and RxHub 28R 29 Join Forces to Deliver Clinical Information Technology Services to Physician Practices 11607 2Founding CEOS of SureScripts 28R 29 and RxHub 28R 29 Join Forces to Deliver Clinical Information Technology Services to Physician Practices 11607 3Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion 3214 1Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion 3214 2Natural Alternatives International Inc Appoints New Chief Financial Officer 11605 1Natural Alternatives International Inc Appoints New Chief Financial Officer 11605 2Natural Alternatives International Inc Appoints New Chief Financial Officer 11605 3
...ng and Colorectal Cancers, ROCKVILLE, Md., April 1... a clinical-stage pharmaceutical company developin...lammatory diseases,announced the presentation of ...ounds. The data were presented by EntreMed scienti...h (AACR) Annual,Meeting in Los Angeles, California...
...utic approach for the treatment,of early and metas...PRNewswire-FirstCall/ - AEterna,Zentaris Inc. , a ...d on endocrine therapy and oncology, today present...th hormone-releasing,hormone (GHRH) antagonist JMR... for Cancer Research (AACR) Annual Meeting being h...
Other Medicine Technology:EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 2EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 3EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models 4AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:7/3/2009)... "This is an opportunity for you...ng our Diabetic Free pills, you will experience a ...betes: your blood sugar, cholesterol levels and bl... be revitalized and your mind will finally be free... of a diabetes patient." , ...
(Date:7/3/2009)... Upstate HomeCare, a home medical ser... medication, respiratory and DME services, is expa...ened. One specializes in home infusion therapy and...state HomeCare. , Clinton...a home medical services provider specializing in i...
(Date:7/2/2009)... at Singapore,s Bioprocessing Technology Institute...ene, "Fas-apoptosis inhibitory molecule" (FAIM), p..., or programmed cell death. , Their research is...Differentiation . , The scientists, Jianxin Huo,...t this process may possibly be manipulated for cli...
(Date:7/2/2009)... July 2 Recent news rep...credentials and ensuring that physicians meet high...ding to the American Board of Medical Specialties ...r Boards in their efforts to develop and implement...aluation and certification of physician specialist...
Breaking Medicine News(10 mins):Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 2Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 3Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 4Health News:Upstate HomeCare Expands, Adds Pharmacies 2Health News:Upstate HomeCare Expands, Adds Pharmacies 3Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4
...ife’s most distressing events, bringing in its wak...standable, and normal, reaction to the disease, bu...h an association, depression has been considered t... also on the initiation, of cancer. Reactive oxyge...
...ble neurodegenerative disorder with no known cause...known at that time, we have come a long way in und...characterized by symptoms of memory loss, confusio...nges, disorientation and loss of language skills. ...
...ts approximately one in every 1,000 children and i...eral genetic and environmental factors have been a... of the condition typically occurs before the age ...le. However, targeted treatment has been shown to ...
... as it is commonly known is a silent killer becaus...ening disease. However, it can lead to a lot of co...idney failure if left untreated. Fortunately, it c...ination and treatment involves the use of anti-hyp...
Other Medicine News:Health News:Depression May Be A Risk Factor For Cancer Initiation 2Health News:PET Scanning can help in early detection of Alzheimer’s diseas 2Health News:Guidelines for treatment of juvenile idiopathic arthritis formulated 2Health News:Common, cheaper drugs could be used to treat hypertension 2
...s-Using a proprietary and patented technology, ADI...ens, called Antigen-Antibody pens-TM, that will al...ing membranes in any form or shape or size. A spec... to see antigen being written on the membrane. One...
...s-Using a proprietary and patented technology, ADI...ens, called Antigen-Antibody pens-TM, that will al...ing membranes in any form or shape or size. A spec... to see antigen being written on the membrane. One...
...plete, Compact Systems for the Storage and Distrib.... Storage and Distribution Systems are designed to...d by Elix or RiOs systems, and to maintain consist...ection against airborne contamination and distribu...
...ltrapure water systems designed to match specific ...illi-Q systems is designed to specifically target ...s such as HPLC, molecular biology and ICP-MS. The ...onitor that records conductivity or resistivity (c...
Medicine Products: